Immunome, Inc.

NASDAQ:IMNM

Biotechnology

Healthcare
$16.78 -2.26%

-$0.42 today

Market cap
$1.98B
Beta
2.07
P/E (TTM)
-9.1
EPS (TTM)
-$1.99
52W Low $7.96High $27.65

Volume 1.41M

Average 1.23M

IMNM Total Debt

Short-term and long-term borrowings combined.

Immunome, Inc.NASDAQ: IMNM

Total Debt · Q3 FY2026 · quarter ended Sep 2026

Total debt rises 155.6% from a year ago

Total debt stood at $10.26M at the end of Q3 FY2026, up 155.6% from a year earlier and up 123.6% from the prior quarter. Over 3 fiscal years it compounded at +136.6% a year.

Context

  • Total debt amounted to 2.0% of total assets at the end of Q3 FY2026, up 0.7 pp from a year earlier.
  • Total debt increased in 2 of the last 3 fiscal years.

What to watch

Whether total debt keeps rising in the next quarterly balance sheet after a +155.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$10.26M+123.6% QoQ
Last fiscal yearDec 2025
$3.86M-20.2% YoY
Year agoSep 2025
$4.01M+155.6% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+155.6%——
1 year-20.2%——
3-year CAGR+136.6%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
3.86M USD
Year-over-year change
-20.2%
4-year CAGR
+86.7%

Total Debt vs competitors

How IMNM compares with its peers on the latest reported figures

  • Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +155.6% is the 3rd highest of 11, against a peer median of -1.0%.
  • Total debt amounts to 2.0% of total assets for IMNM, versus a peer median of 1.9%.
IMNM Competitors
Total Debt for IMNM and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IMCRImmunocore Holdings plcMar 2026$435.68M USD+0.4%+75.0%40.6%
MGNXMacroGenics, Inc.Mar 2026$36.51M USD-2.6%+45.3%16.8%
BCYCBicycle Therapeutics plcMar 2026$15.34M USD+68.2%-26.6%2.4%
IMTXImmatics N.V.Mar 2026€15.1M EUR-17.9%+2.4%2.8%
STROSutro Biopharma, Inc.Mar 2026$13.63M USD-36.3%-34.2%5.6%
IMNMImmunome, Inc.Sep 2026$10.26M USD+155.6%+136.6%2.0%
CLDXCelldex Therapeutics, Inc.Sep 2026$9.87M USD+276.6%-16.6%1.4%
IMMXImmix Biopharma, Inc.Mar 2026$1.04M USD-2.0%—1.1%
CRVSCorvus Pharmaceuticals, Inc.Mar 2026$834K USD-27.7%-28.8%0.3%
SLSSELLAS Life Sciences Group, Inc.Sep 2026$599K USD+0.0%+1.9%0.4%
AVBPArriVent BioPharma, Inc. Common StockMar 2026$419K USD+203.6%-53.5%0.1%
Peer median (excluding IMNM) —-1.0%-16.6%1.9%

Competitors are the stored peer set for IMNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents49.23M20.32M98.68M143.35M653.48M
Short-term Investments0039.46M73.95M0
Net Receivables4.31M847K289K00
Inventory00000
Other Current Assets004.99M4.04M7.3M
Total Current Assets56.64M22.65M144.7M221.34M660.78M
Property, Plant & Equipment (Net)855K965K3.64M14.39M17.61M
Goodwill00000
Intangible Assets00000
Long-term Investments100K0100K0210K
Tax Assets00000
Other Non-current Assets332K432K100K4.51M4.59M
Total Non-current Assets1.29M1.4M3.84M18.9M22.41M
Total Assets57.93M24.05M148.54M240.24M683.19M
Account Payables3.08M2.4M3.31M14.19M3.34M
Short-term Debt00000
Tax Payables00000
Deferred Revenue0010.49M6.94M0
Other Current Liabilities2.02M1.96M4.98M8M15.15M
Total Current Liabilities9.73M7.33M21.83M54.31M44.99M
Long-term Debt00003.86M
Deferred Tax Liabilities00(5.49M)00
Deferred Revenue (Non-current)005.49M00
Other Non-current Liabilities12K05.49M00
Total Non-current Liabilities12K62K6.83M4.77M3.86M
Total Liabilities9.74M7.39M28.66M59.08M48.85M
Common Stock1K1K4K6K11K
Retained Earnings(79.11M)(116M)(222.81M)(515.77M)(728.16M)
Accumulated OCI(57.93M)022K57K0
Other Stockholders Equity00000
Minority Interest00000
Total Equity48.19M16.65M119.88M181.17M634.34M
Total Debt317K291K1.65M4.83M3.86M
Net Debt(48.91M)(20.03M)(97.03M)(138.52M)(649.63M)

Immunome, Inc.

NASDAQ:IMNM

Intrinsic Alpha fair value

Locked

Current Price

$16.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.